Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

“Why is PMDD so difficult to treat, and what help might a new trial offer to those who suffer?” Founded in 1946, ‘Woman’s Hour&rsquo...
Asarina Pharma Annual Report for 2018 released 2019-04-17 08:00 Regulatory Annual
For further information see the attached, plus please visit www.asarinapharma.com For further information, please contact: Peter Nordkild, CEO, Asarina...
- Number of directors: six (6) - Annual remuneration to the Board of Directors: SEK 500,000 to the Chairman of the Board and SEK 200,000...
Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per May 2nd, 2019, and who, no later...
The research group led by Prof. Marco Bortolato at the University of Utah has found that Sepranolone reduces the number of tic-like responses in the D1CT-7...
Asarina Pharma Year-End Report 2018 shows solid progress 2019-02-25 08:30 Regulatory Interim
Fourth Quarter 2018: FINANCIAL HIGHLIGHTS We received SEK 6.3 million in October in proceeds from the green shoe connected to the IPO. We maintained strict...
Migraine is more prevalent than diabetes, epilepsy and asthma combined, three times more women than men suffer from it, and 1-in-5 of those suffer from...
The event began with Lisa Stenberg, author of the best-selling Bli vän med din PMS (Make friends with your PMS). Lisa emphasized the importance of...
Interim Report July-September 2018 2018-11-14 08:00 Regulatory Interim
Third Quarter Highlights Key financials 1 July – 30 September 2018 - Net sales: SEK 0 (0) - Operating loss: SEK 14.6M (Loss: 3.6M) - Earnings per...
On November 21 2018 Asarina Pharma CSO Torbjörn Bäckström and COO Karin Ekberg will join Swedish celebrities and scientists as they present...